Interleukin-6: A villain in the drama of pancreatic cancer development and progression

Hepatobiliary and Pancreatic Diseases International

Volumn 13, Issue 4, 2014, Pages 371-380

  Holmer, Reinhild ^a   Goumas, Freya A ^a   Waetzig, Georg H ^b   Rose John, Stefan ^c   Kalthoff, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b University Hospital Schleswig Holstein ^*  (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

IL 6 signaling; IL 6 trans signaling; pancreatic ductal adenocarcinoma; sgp130Fc; targeted therapy; tumor microenvironment; tumor stroma

Indexed keywords

INTERLEUKIN 6; MESOTHELIN; ANTINEOPLASTIC AGENT; AUTACOID; IL6 PROTEIN, HUMAN; TUMOR MARKER;

ANGIOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CORRELATION ANALYSIS; EXPERIMENTAL MOUSE; HUMAN; IN VITRO STUDY; INFLAMMATION; MEDLINE; MICROENVIRONMENT; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; DISEASE COURSE; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84923038228     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(14)60259-9     Document Type: Review

References (97)

1. M Malvezzi, P Bertuccio, F Levi, C La Vecchia, E Negri European cancer mortality predictions for the year 2013 Ann Oncol 24 2013 792 800
2. J Ferlay, E Steliarova-Foucher, J Lortet-Tieulent, S Rosso, JW Coebergh, H Comber et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
3. American Cancer Society Cancer facts & figures - 2013, 2013 [cited 2014 Apr 10] 2013 Jan 2 Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
4. A Maitra, RH Hruban Pancreatic cancer Annu Rev Pathol 3 2008 157 188
5. M Hidalgo Pancreatic cancer N Engl J Med 362 2010 1605 1617
6. A Kleger, L Perkhofer, T Seufferlein Smarter drugs emerging in pancreatic cancer therapy Ann Oncol 2014 Mar 14
7. A Neesse, P Michl, KK Frese, C Feig, N Cook, MA Jacobetz et al. Stromal biology and therapy in pancreatic cancer Gut 60 2011 861 868
8. C Feig, A Gopinathan, A Neesse, DS Chan, N Cook, DA Tuveson The pancreas cancer microenvironment Clin Cancer Res 18 2012 4266 4276
9. S Hinz, L Pagerols-Raluy, HH Oberg, O Ammerpohl, S Grüssel, B Sipos et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer Cancer Res 67 2007 8344 8350
10. A Evans, E Costello The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion Front Physiol 3 2012 270
11. CW Steele, NB Jamieson, TR Evans, CJ McKay, OJ Sansom, JP Morton et al. Exploiting inflammation for therapeutic gain in pancreatic cancer Br J Cancer 108 2013 997 1003
12. RH Vonderheide, LJ Bayne Inflammatory networks and immune surveillance of pancreatic carcinoma Curr Opin Immunol 25 2013 200 205
13. R Roshani, F McCarthy, T3 Hagemann Inflammatory cytokines in human pancreatic cancer Cancer Lett 345 2014 157 163
14. M Lesina, SM Wörmann, P Neuhöfer, L Song, H2 Algül Interleukin-6 in inflammatory and malignant diseases of the pancreas Semin Immunol 26 2014 80 87
15. MA Collins, M2 Pasca di Magliano Kras as a key oncogene and therapeutic target in pancreatic cancer Front Physiol 4 2014 407
16. R Reznik, AE Hendifar, R Tuli Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma Front Physiol 5 2014 87
17. C Röder, A Trauzold, H Kalthoff Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma Eur J Cell Biol 90 2011 450 455
18. ID Kyriazanos, GG Tsoukalos, G Papageorgiou, KE Verigos, L Miliadis, CN Stoidis Local recurrence of pancreatic cancer after primary surgical intervention: how to deal with this devastating scenario? Surg Oncol 20 2011 e133 e142
19. JH Egberts, B Schniewind, B Sipos, S Hinz, H Kalthoff, J Tepel Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice Cancer Biol Ther 6 2007 1227 1232
20. AA Rucki, L Zheng Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies World J Gastroenterol 20 2014 2237 2246
21. AB Lowenfels, P Maisonneuve, G Cavallini, RW Ammann, PG Lankisch, JR Andersen et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group N Engl J Med 328 1993 1433 1437
22. N Momi, S Kaur, SR Krishn, SK Batra Discovering the route from inflammation to pancreatic cancer Minerva Gastroenterol Dietol 58 2012 283 297
23. AV Pinho, L Chantrill, I3 Rooman Chronic pancreatitis: a path to pancreatic cancer Cancer Lett 345 2014 203 209
24. C Guerra, AJ Schuhmacher, M Cañamero, PJ Grippo, L Verdaguer, L Pérez-Gallego et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice Cancer Cell 11 2007 291 302
25. SY Gidekel Friedlander, GC Chu, EL Snyder, N Girnius, G Dibelius, D Crowley et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras Cancer Cell 16 2009 379 389
26. AD Rhim, ET Mirek, NM Aiello, A Maitra, JM Bailey, F McAllister et al. EMT and dissemination precede pancreatic tumor formation Cell 148 2012 349 361
27. H Funahashi, M Satake, D Dawson, NA Huynh, HA Reber, OJ Hines et al. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor Cancer Res 67 2007 7068 7071
28. BF El-Rayes, MM Zalupski, AF Shields, AM Ferris, U Vaishampayan, LK Heilbrun et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer Invest New Drugs 23 2005 583 590
29. Z Zhang, B Rigas NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review) Int J Oncol 29 2006 185 192
30. JH Egberts, V Cloosters, A Noack, B Schniewind, L Thon, S Klose et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis Cancer Res 68 2008 1443 1450
31. C Wu, SA Fernandez, T Criswell, TA Chidiac, D Guttridge, M Villalona-Calero et al. Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease Pancreas 42 2013 813 818
32. JR Hecht, JJ Farrell, N Senzer, J Nemunaitis, A Rosemurgy, T Chung et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study Gastrointest Endosc 75 2012 332 338
33. W Schmiegel, J Schmielau, D Henne-Bruns, H Juhl, C Roeder, P Buggisch et al. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer Proc Natl Acad Sci U S A 94 1997 12622 12626
34. M Li, Y Zhang, LW Feurino, H Wang, WE Fisher, FC Brunicardi et al. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer Cancer Sci 99 2008 733 737
35. Y Matsuo, N Ochi, H Sawai, A Yasuda, H Takahashi, H Funahashi et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer Int J Cancer 124 2009 853 861
36. Y Guo, F Xu, T Lu, Z Duan, Z Zhang Interleukin-6 signaling pathway in targeted therapy for cancer Cancer Treat Rev 38 2012 904 910
37. X Yao, J Huang, H Zhong, N Shen, R Faggioni, M Fung et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers Pharmacol Ther 141 2014 125 139
38. S Rose-John IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6 Int J Biol Sci 8 2012 1237 1247
39. GH Waetzig, S Rose-John Hitting a complex target: an update on interleukin-6 trans-signalling Expert Opin Ther Targets 16 2012 225 236
40. J Scheller, C Garbers, S Rose-John Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities Semin Immunol 26 2014 2 12
41. H Yu, D Pardoll, R Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 2009 798 809
42. JF Bromberg, MH Wrzeszczynska, G Devgan, Y Zhao, RG Pestell, C Albanese et al. Stat3 as an oncogene Cell 98 1999 295 303
43. DT Fisher, MM Appenheimer, SS2 Evans The two faces of IL-6 in the tumor microenvironment Semin Immunol 26 2014 38 47
44. T Ara, YA Declerck Interleukin-6 in bone metastasis and cancer progression Eur J Cancer 46 2010 1223 1231
45. S Okada, T Okusaka, H Ishii, A Kyogoku, M Yoshimori, N Kajimura et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer Jpn J Clin Oncol 28 1998 12 15
46. MD Barber, KC Fearon, JA Ross Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer Clin Sci (Lond) 96 1999 83 87
47. FA Wenger, CA Jacobi, J Zieren, W Döcke, HD Volk, JM Müller Tumor size and lymph-node status in pancreatic carcinoma - is there a correlation to the preoperative immune function? Langenbecks Arch Surg 384 1999 473 478
48. SJ Wigmore, KC Fearon, K Sangster, JP Maingay, OJ Garden, JA Ross Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer Int J Oncol 21 2002 881 886
49. B Ebrahimi, SL Tucker, D Li, JL Abbruzzese, R Kurzrock Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis Cancer 101 2004 2727 2736
50. G Bellone, A Carbone, C Smirne, T Scirelli, A Buffolino, A Novarino et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells J Immunol 177 2006 3448 3460
51. R Talar-Wojnarowska, A Gasiorowska, B Smolarz, H Romanowicz-Makowska, A Kulig, E Malecka-Panas Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis Dig Dis Sci 54 2009 683 689
52. B Mroczko, M Groblewska, M Gryko, B Kedra, M Szmitkowski Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis J Clin Lab Anal 24 2010 256 261
53. M Lesina, MU Kurkowski, K Ludes, S Rose-John, M Treiber, G Klöppel et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer Cancer Cell 19 2011 456 469
54. RB Corcoran, G Contino, V Deshpande, A Tzatsos, C Conrad, CH Benes et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis Cancer Res 71 2011 5020 5029
55. G Bellone, C Smirne, FA Mauri, E Tonel, A Carbone, A Buffolino et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival Cancer Immunol Immunother 55 2006 684 698
56. S Mitsunaga, M Ikeda, S Shimizu, I Ohno, J Furuse, M Inagaki et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer Br J Cancer 108 2013 2063 2069
57. AG Moses, J Maingay, K Sangster, KC Fearon, JA Ross Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival Oncol Rep 21 2009 1091 1095
58. ME Martignoni, P Kunze, W Hildebrandt, B Künzli, P Berberat, T Giese et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia Clin Cancer Res 11 2005 5802 5808
59. J Bachmann, K Ketterer, C Marsch, K Fechtner, H Krakowski-Roosen, MW Büchler et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function BMC Cancer 9 2009 255
60. KC Fearon, VE Baracos Cachexia in pancreatic cancer: new treatment options and measures of success HPB (Oxford) 12 2010 323 324
61. D Zhang, Y Zhou, L Wu, S Wang, H Zheng, B Yu et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer Ann Clin Lab Sci 38 2008 113 119
62. ME Martignoni, C Dimitriu, J Bachmann, H Krakowski-Rosen, K Ketterer, R Kinscherf et al. Liver macrophages contribute to pancreatic cancer-related cachexia Oncol Rep 21 2009 363 369
63. BE Barton IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation Immunol Res 23 2001 41 58
64. JA Carson, KA Baltgalvis Interleukin 6 as a key regulator of muscle mass during cachexia Exerc Sport Sci Rev 38 2010 168 176
65. UH Weidle, S Klostermann, D Eggle, A Krüger Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer Cancer Genomics Proteomics 7 2010 287 302
66. KC Fearon, DJ Glass, DC Guttridge Cancer cachexia: mediators, signaling, and metabolic pathways Cell Metab 16 2012 153 166
67. Y Zhang, W Yan, MA Collins, F Bednar, S Rakshit, BR Zetter et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance Cancer Res 73 2013 6359 6374
68. LW Feurino, Y Zhang, U Bharadwaj, R Zhang, F Li, WE Fisher et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells Cancer Biol Ther 6 2007 1096 1100
69. FM Johnston, MC Tan, BR Tan Jr, MR Porembka, EM Brunt, DC Linehan et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer Clin Cancer Res 15 2009 6511 6518
70. AE Cha Jack Andraka, Maryland's boy wonder, on mean scientists, homecoming and tricorders. The Washington Post [serial online], 2013 [cited 2014 Apr 10] Available from: http://www.washingtonpost.com/national/health-science/jack-andraka-marylands-boy-wonder-on-mean-scientists-homecoming-and-tricorders/2013/12/02/e15606be-4173-11e3-a624-41d661b0bb78-story.html
71. U Bharadwaj, C Marin-Muller, M Li, C Chen, Q Yao Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation Carcinogenesis 32 2011 1013 1024
72. R Kang, T Loux, D Tang, NE Schapiro, P Vernon, KM Livesey et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia Proc Natl Acad Sci U S A 109 2012 7031 7036
73. B Ancrile, KH Lim, CM Counter Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis Genes Dev 21 2007 1714 1719
74. Y Zhang, U Bharadwaj, CD Logsdon, C Chen, Q Yao, M Li ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB Clin Cancer Res 16 2010 1423 1430
75. B Bao, S Ali, A Ahmad, AS Azmi, Y Li, S Banerjee et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment PLoS One 7 2012 e50165
76. H Liu, Q Ma, Q Xu, J Lei, X Li, Z Wang et al. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer Curr Pharm Des 18 2012 2395 2403
77. D Tang, D Wang, Z Yuan, X Xue, Y Zhang, Y An et al. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma Int J Cancer 132 2013 993 1003
78. T Masui, R Hosotani, R Doi, Y Miyamoto, S Tsuji, S Nakajima et al. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction Anticancer Res 22 2002 4093 4100
79. RF Tang, SX Wang, FR Zhang, L Peng, SX Wang, Y Xiao et al. Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer Hepatobiliary Pancreat Dis Int 4 2005 460 463
80. C Huang, G Yang, T Jiang, K Huang, J Cao, Z Qiu Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro J Exp Clin Cancer Res 29 2010 51
81. SP Huang, MS Wu, CT Shun, HP Wang, MT Lin, ML Kuo et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma J Biomed Sci 11 2004 517 527
82. LH Wei, ML Kuo, CA Chen, CH Chou, KB Lai, CN Lee et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway Oncogene 22 2003 1517 1527
83. JS Wey, MJ Gray, F Fan, A Belcheva, MF McCarty, O Stoeltzing et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells Br J Cancer 93 2005 233 241
84. K Saito, H Ishikura, T Kishimoto, Y Kawarada, T Yano, T Takahashi et al. Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression Int J Cancer 75 1998 284 289
85. M Herreros-Villanueva, E Hijona, A Cosme, L Bujanda Mouse models of pancreatic cancer World J Gastroenterol 18 2012 1286 1294
86. M Fischer, J Goldschmitt, C Peschel, JP Brakenhoff, KJ Kallen, A Wollmer et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion Nat Biotechnol 15 1997 142 145
87. A Fukuda, SC Wang, JP Morris 4th, AE Folias, A Liou, GE Kim et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression Cancer Cell 19 2011 441 455
88. MC Bibby Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages Eur J Cancer 40 2004 852 857
89. MB Wachsmann, LM Pop, ES Vitetta Pancreatic ductal adenocarcinoma: a review of immunologic aspects J Investig Med 60 2012 643 663
90. TB Dorff, B Goldman, JK Pinski, PC Mack, PN Lara Jr, PJ Van Veldhuizen Jr et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res 16 2010 3028 3034
91. PM Voorhees, RF Manges, P Sonneveld, S Jagannath, G Somlo, A Krishnan et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma Br J Haematol 161 2013 357 366
92. S Shinriki, H Jono, K Ota, M Ueda, M Kudo, T Ota et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma Clin Cancer Res 15 2009 5426 5434
93. K Ando, F Takahashi, S Motojima, K Nakashima, N Kaneko, K Hoshi et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia J Clin Oncol 31 2013 e69 e72
94. TJ Bayliss, JT Smith, M Schuster, KH Dragnev, JR Rigas A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer Expert Opin Biol Ther 11 2011 1663 1668
95. J Hoge, I Yan, N Jänner, V Schumacher, A Chalaris, OM Steinmetz et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling J Immunol 190 2013 703 711
96. J Sodenkamp, GH Waetzig, J Scheller, D Seegert, J Grötzinger, S Rose-John et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis Immunobiology 217 2012 996 1004
97. W Breitbart, B Rosenfeld, K Tobias, H Pessin, GY Ku, J Yuan et al. Depression, cytokines, and pancreatic cancer Psychooncology 23 2014 339 345